T-cell immunotherapy is a therapy which will boost the immune system. Various clinical trials are going on for treatment of diseases such as acute lymphoblastic leukemia, acute myeloid leukemia, brain and central nervous system tumors, neuroblastoma, and solid tumors. T cells are cells which fights against the antigens. These cells are a normal part of our immune system. They are present throughout the body to attack abnormal cells. One of the therapy of T-cell immunotherapy is CAR T-cell which helps in improving the functioning of T- cells. T-cells in this therapy are removed from the body and modified so that they can fight cancer. The CAR protein helps and assists T-cells find and target cancer cells to be killed. The T-cells divide and give rise to more cells which is also considered one time treatment. This T- cell immunotherapy treatment is a onetime treatment and can continue to be active in the body for a long time. Majorly the T-Cell Immunotherapy is used in people with large B-cells whose cancer has been progressed.
Increase in the population suffering from cancer is the major cause for continuous research and development of T- cell immunotherapy market. Cancer has accounted for almost 0.6 million deaths in 2017 in the US alone. Also according to the WHO number of new cases for cancer are expected to rise 70% in the years to come. Conventional treatments such as Chemotherapy, radiation therapy have limited efficacy in last stages of cancers. Moreover radiation and chemotherapy are associated with many side effects which are expected to increase the T-cell immunotherapy market. The conventional treatments slow down the progression of disease however chances of recurrence are more. T-cell immunotherapy has expected to assure in the treatment of cancer even in advanced stages.
Many initiatives are being taken to develop more effective and anti-cancer therapies, one of which is T-cell immunotherapy which is expected to be highly effective to eradicate anti-cancer therapies.
Tentatively, T-Cell Immunotherapy Market has been segmented on the basis of product type, applications and end user.
On the basis of Product type, T-Cell Immunotherapy Market can be segmented as:
On the basis of Applications, T-Cell Immunotherapy Market can be segmented as:
- Kidney Cancer
- Lung Cancer
- Breast Cancer
- Colorectal Cancer
On the basis of end users, T-Cell Immunotherapy Market can be segmented as:
- Long Term Care Facilities
- Ambulatory surgical Centers
Demand for T-Cell Immunotherapy will increase as due to increase in the patient pool suffering from cancer. Also these therapies are providing measures which will improve the treatment for cancer.
Geographically, global T-Cell Immunotherapy Market is divided into regions viz. Latin America, North America, Western Europe, Middle East & Africa, Asia Pacific, and Eastern Europe. In terms of country US is expected to be the growing market due to the advanced T-Cell Immunotherapy and patient care being the top most priority. T-Cell Immunotherapy Market is spreading because of increasing patient care, also it reduces the recurrence of cancer which would further make a positive impact on the patient’s health conditions. Also it could reduce the risks of infections. Rise in the health care expenditure and improvement in the government support are some of the additional factors which will effect over the forecast period for the T-Cell Immunotherapy Market. T-cell Immunotherapy market is expected to provide gainful opportunities for the manufacturers in future.
Some of the major market players in the Global T-Cell Immunotherapy Market identified across the value chain include: bluebird bio, Adaptimmune Therapeutics, Novartis, Innovative Cellular Therapeutics, Sinobioway Cell Therapy, CARsgen Therapeutics, Cellectis, Altor Bioscience Corporation, Juno Therapeutics, Takara Bio, Kite Pharma Celgene and Autolu,. The T-Cell Immunotherapy Market report provides in-depth analysis of parent market trends, governing factors and macro-economic indicator and along with market attractiveness as per segments. Also the report is a compilation of qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report also outlines the qualitative impact of different market factors on market segments and geographies.
The report T-Cell Immunotherapy Market covers exhaustive analysis on:
- Market Segments
- Market Dynamics
- Market Size
- Supply & Demand
- Current Trends/Issues/Challenges
- Competition & Companies involved
- Value Chain
Regional analysis includes
- North America (U.S., Canada)
- Latin America (Argentina, Mexico, Brazil)
- Europe (Germany, Italy, U.K, Spain, France, Russia, Poland)
- Asia Pacific Excluding Japan (India, Australia & New Zealand, China, ASEAN)
- Middle East and Africa (GCC, South Africa, Rest Of MEA)
- Detailed overview of parent market
- Changing market dynamics in the industry
- In-depth market segmentation
- Historical, current and projected market size for T-Cell Immunotherapy Market in terms of volume and value
- Recent industry trends and developments
- Competitive landscape
- Strategies of key players and products offered
- Potential and niche segments, geographical regions exhibiting promising growth
- A neutral perspective on T-Cell Immunotherapy Market performance
- Must-have information for market players to sustain and enhance their market footprint.